Artivion, Inc. (AORT)

NYSE: AORT · Real-Time Price · USD
28.71
-0.27 (-0.93%)
Nov 8, 2024, 4:00 PM EST - Market closed
-0.93%
Market Cap 1.20B
Revenue (ttm) 384.90M
Net Income (ttm) -728,000
Shares Out 41.92M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE 276.06
Dividend n/a
Ex-Dividend Date n/a
Volume 370,087
Open 29.50
Previous Close 28.98
Day's Range 27.12 - 29.50
52-Week Range 13.18 - 30.00
Beta 1.75
Analysts Strong Buy
Price Target 31.00 (+7.98%)
Earnings Date Nov 7, 2024

About AORT

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shel... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Feb 11, 1993
Employees 1,500
Stock Exchange NYSE
Ticker Symbol AORT
Full Company Profile

Financial Performance

In 2023, Artivion's revenue was $354.00 million, an increase of 12.82% compared to the previous year's $313.79 million. Losses were -$30.57 million, 60.1% more than in 2022.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for AORT stock is "Strong Buy." The 12-month stock price forecast is $31.0, which is an increase of 7.98% from the latest price.

Price Target
$31.0
(7.98% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Artivion, Inc. (AORT) Q3 2024 Earnings Call Transcript

Artivion, Inc. (NYSE:AORT) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Ch...

1 day ago - Seeking Alpha

Artivion Reports Third Quarter 2024 Financial Results

Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP cons...

3 days ago - PRNewsWire

Artivion to Participate in Upcoming Investor Conferences

ATLANTA , Nov. 5, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming i...

5 days ago - PRNewsWire

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial Results

ATLANTA , Oct. 24, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2024 financial results...

17 days ago - PRNewsWire

Artivion Announces Presentation of Late-Breaking Clinical Data at the 38th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting

5-Year Data from the AMDS DARTS Trial Demonstrates Positive Aortic Remodeling with 94% of Patients Free from Unanticipated Reoperation 30-Day Data from the AMDS PERSEVERE Trial Shows Cerebral Malperfu...

4 weeks ago - PRNewsWire

Artivion, Inc. (AORT) Q2 2024 Earnings Call Transcript

Artivion, Inc. (NYSE:AORT) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief ...

3 months ago - Seeking Alpha

Artivion Reports Second Quarter 2024 Financial Results

Second Quarter Highlights:  Achieved revenue of $98.0 million in the second quarter of 2024 versus $89.3 million in the second quarter of 2023, an increase of 10% on both a GAAP and constant currency ...

3 months ago - PRNewsWire

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2024 Financial Results

ATLANTA , July 25, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2024 financial result...

3 months ago - PRNewsWire

Artivion Amends Agreements with Endospan

Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS Upfront Payment Associated with Purchase Option Reduced to $135 million, inclusive of loan off-set, and $...

4 months ago - PRNewsWire

Data-Driven Growth Fuels More Upside For Overlooked Artivion

Artivion, Inc. has continued to log double-digit revenue growth with contributions from diverse assets including its stent grafts, heart valves, and cryopreserved tissue grafts. Positive post-approval...

5 months ago - Seeking Alpha

Artivion, Inc. (AORT) Q1 2024 Earnings Call Transcript

Artivion, Inc. (NYSE:AORT) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Eileen Martin - Investor Relations Pat Mackin - Chief Executive Officer Lance Berry - Chief Fin...

6 months ago - Seeking Alpha

Artivion Reports First Quarter 2024 Financial Results

First Quarter Highlights: Achieved revenue of $97.4 million in the first quarter of 2024 versus $83.2 million in the first quarter of 2023, an increase of 17% on a GAAP basis and 16% on a non-GAAP con...

6 months ago - PRNewsWire

Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting

5-Year Real-World Safety and Efficacy Data from On-X Aortic Heart Valve Low INR Post-Market Study Demonstrate Even Better Patient Outcomes Than Predicted by the PROACT IDE Study Late-Breaking 30-Day D...

6 months ago - PRNewsWire

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results

ATLANTA , April 22, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2024 financial result...

7 months ago - PRNewsWire

Artivion to Participate in the 23rd Annual Needham Virtual Healthcare Conference

ATLANTA, April 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the ...

7 months ago - PRNewsWire

Artivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

ATLANTA , March 6, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the...

8 months ago - PRNewsWire

Artivion, Inc. (AORT) Q4 2023 Earnings Call Transcript

Artivion, Inc. (AORT) Q4 2023 Earnings Call Transcript

9 months ago - Seeking Alpha

Artivion Reports Fourth Quarter and Full Year 2023 Financial Results

Fourth Quarter and Recent Business Highlights: Achieved revenue of $93.7 million in the fourth quarter of 2023 versus $79.4 million in the fourth quarter of 2022, an increase of 18% on a GAAP basis an...

9 months ago - PRNewsWire

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial Results

ATLANTA , Feb. 1, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2023 fin...

10 months ago - PRNewsWire

Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting

Full IDE Data Set Demonstrates Statistically Significant Reduction of All-Cause Mortality and Primary Major Adverse Events (MAEs) at 30 days with use of AMDS in Acute DeBakey Type I (ADTI) Dissections...

10 months ago - PRNewsWire

Artivion Obtains $350 Million in Senior Secured Credit Facilities

Non-Dilutive Financing Provides Comprehensive Solution to Address Debt Maturities  and Provide Flexibility to Further Optimize Capital Structure ATLANTA , Jan. 18, 2024 /PRNewswire/ -- Artivion, Inc. ...

Other symbols: ARES
10 months ago - PRNewsWire

Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D.

Reaffirms Financial Guidance Provided on November 2, 2023 ATLANTA , Dec. 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease t...

1 year ago - PRNewsWire

Artivion Announces Completion of Enrollment in PERSEVERE Trial

ATLANTA , Nov. 9, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed enrollment in the PE...

1 year ago - PRNewsWire

Artivion, Inc. (AORT) Q3 2023 Earnings Call Transcript

Artivion, Inc. (NYSE:AORT) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group Pat Mackin - Chairman, President, and Chief Executive Offic...

1 year ago - Seeking Alpha

Artivion Reports Third Quarter 2023 Financial Results

Third Quarter and Recent Business Highlights: Achieved revenue of $87.9 million in the third quarter of 2023 versus $76.8 million in the third quarter of 2022, an increase of 14% on a GAAP basis and 1...

1 year ago - PRNewsWire